These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 33884506

  • 1. Periosteal reaction of medication-related osteonecrosis of the jaw (MRONJ): clinical significance and changes during conservative therapy.
    Soutome S, Otsuru M, Hayashida S, Yanamoto S, Sasaki M, Takagi Y, Sumi M, Kojima Y, Sawada S, Iwai H, Umeda M, Saito T.
    Support Care Cancer; 2021 Nov; 29(11):6361-6368. PubMed ID: 33884506
    [Abstract] [Full Text] [Related]

  • 2. Imaging findings and treatment outcomes of a rare subtype of medication-related osteonecrosis of the jaw.
    Otsuru M, Soutome S, Hayashida S, Yanamoto S, Sasaki M, Takagi Y, Sumi M, Umeda M.
    J Bone Miner Metab; 2022 Jan; 40(1):150-156. PubMed ID: 34510261
    [Abstract] [Full Text] [Related]

  • 3. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study.
    Ristow O, Rückschloß T, Müller M, Berger M, Kargus S, Pautke C, Engel M, Hoffmann J, Freudlsperger C.
    J Craniomaxillofac Surg; 2019 Mar; 47(3):491-499. PubMed ID: 30642734
    [Abstract] [Full Text] [Related]

  • 4. Medication-related osteonecrosis of the jaw without osteolysis on computed tomography: a retrospective and observational study.
    Sakamoto Y, Sawada S, Kojima Y.
    Sci Rep; 2023 Aug 09; 13(1):12890. PubMed ID: 37558709
    [Abstract] [Full Text] [Related]

  • 5. Factors Exacerbating Clinical Symptoms and CT Findings in Patients with Medication-Related Osteonecrosis of the Jaw Receiving Conservative Therapy: A Multicenter Retrospective Study of 53 Cases.
    Kojima Y, Soutome S, Otsuru M, Hayashida S, Sakamoto Y, Sawada S, Umeda M.
    Int J Environ Res Public Health; 2022 Jun 26; 19(13):. PubMed ID: 35805513
    [Abstract] [Full Text] [Related]

  • 6. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A, Goto TK, Ojiri H, Takagiwa M, Hiraga C, Okamura M, Hasegawa S, Okuyama Y, Ogino N, Yamauchi H, Kobashi Y, Yamazoe S, Munetomo Y, Mogami T, Nomura T.
    Dentomaxillofac Radiol; 2018 May 26; 47(4):20170323. PubMed ID: 29365278
    [Abstract] [Full Text] [Related]

  • 7. Effect of periosteal reaction in medication-related osteonecrosis of the jaw on treatment outcome after surgery.
    Soutome S, Yanamoto S, Sumi M, Hayashida S, Kojima Y, Sawada S, Rokutanda S, Iwai H, Saito T, Umeda M.
    J Bone Miner Metab; 2021 Mar 26; 39(2):302-310. PubMed ID: 33047190
    [Abstract] [Full Text] [Related]

  • 8. Risk factors associated with prognosis of patients with medication-related osteonecrosis of the jaw.
    Tadokoro Y, Hasegawa T, Takeda D, Murakami A, Yatagai N, Arimoro S, Iwata E, Saito I, Kusumoto J, Akashi M.
    Head Neck; 2024 Feb 26; 46(2):282-290. PubMed ID: 37962011
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. How does the clinical and tomographic appearance of MRONJ influences its treatment prognosis?
    Moreno Rabie C, García-Larraín S, Contreras Diez de Medina D, Cabello-Salazar I, Fontenele RC, Van den Wyngaert T, Jacobs R.
    Dentomaxillofac Radiol; 2023 Nov 26; 52(8):20230304. PubMed ID: 37870051
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Microarchitecture of medication-related osteonecrosis of the jaw (MRONJ); a retrospective micro-CT and morphometric analysis.
    Schoenhof R, Munz A, Yuan A, ElAyouti A, Boesmueller H, Blumenstock G, Reinert S, Hoefert S.
    J Craniomaxillofac Surg; 2021 Jun 26; 49(6):508-517. PubMed ID: 33707134
    [Abstract] [Full Text] [Related]

  • 15. Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up.
    Nisi M, Karapetsa D, Gennai S, Ramaglia L, Graziani F, Gabriele M.
    J Craniomaxillofac Surg; 2018 Jul 26; 46(7):1153-1158. PubMed ID: 29802059
    [Abstract] [Full Text] [Related]

  • 16. Surgical and conservative treatment outcomes of medication-related osteonecrosis of the jaw located at tori: a retrospective study.
    Amin H, Andersen SWM, Jensen SS, Kofod T.
    Oral Maxillofac Surg; 2024 Sep 26; 28(3):1117-1125. PubMed ID: 38418702
    [Abstract] [Full Text] [Related]

  • 17. The status of jaw lesions and medication-related osteonecrosis of jaw in patients with multiple myeloma.
    Lu SY, Ma MC, Wang MC, Hsue SS.
    J Formos Med Assoc; 2021 Nov 26; 120(11):1967-1976. PubMed ID: 33551311
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw: a case- and literature-based review.
    Yamada SI, Kurita H, Kondo E, Suzuki S, Nishimaki F, Yoshimura N, Morioka M, Ishii S, Kamata T.
    Clin Oral Investig; 2019 Aug 26; 23(8):3203-3211. PubMed ID: 30406491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.